Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: A follow-on study to a randomized clinical trial

Pediatric Infectious Disease Journal

Volumn 32, Issue 10, 2013, Pages 1116-1121

  Snape, Matthew D ^a   Philip, John ^a   John, Tessa M ^a   Robinson, Hannah ^a   Kelly, Sarah ^a   Gossger, Nicoletta ^a   Yu, Ly Mee ^b   Kittel, Claudia ^c   Toneatto, Daniela ^c   Dull, Peter M ^d   Pollard, Andrew J ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^d Novartis Vaccines and Diagnostics Inc   (United States)

Author keywords

Persistence; Serogroup B meningococcal vaccine

Indexed keywords

BACTERIUM ANTIBODY; MENINGOCOCCUS VACCINE;

ARTICLE; BACTERIAL STRAIN; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SERUM BACTERICIDAL ANTIBODY ASSAY; TREATMENT RESPONSE;

ANTIBODIES, BACTERIAL; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFANT; MALE; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS;

EID: 84891829606     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31829cfff2     Document Type: Article

References (20)

1. Snape MD, Dawson T, Oster P, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J. 2010;29:e71-e79.
2. Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51: 1127-1137.
3. Gossger N, Snape MD, Yu LM, et al.; European MenB Vaccine Study Group. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307: 573-582.
4. Santolaya ME, O'Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observerblind, placebo-controlled study. Lancet. 2012;379: 617-24.
5. Ladhani SN, Flood JS, Ramsay ME et al. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine. 2102;30: 3710-3716.
6. Ladhani SN, Flood JS, Ramsay ME, et al. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine. 2012;30: 3710-3716.
7. Holst J, Feiring B, Fuglesang JE, et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine. 2003;21: 734-737.
8. Galloway Y, Stehr-Green P, McNicholas A, et al. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol. 2009;38: 413-418.
9. Jackson C, Lennon D, Wong S, et al. Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers. Arch Dis Child. 2011;96: 744-751.
10. Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364: 365-367.
11. Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A. 2010;107: 19490-19495.
12. Vogel U, Taha MK, Vazquez JA, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013;13: 416-425.
13. Smith HNM, Sloots T, Tozer S, et al. Estimating the potential strain coverage in Australia of a multicomponent vaccine targeting serogroup B meningococci. Presented at: 7th World Congress of the World Society for Pediatric Infectious Diseases (WSPID); November 16-19, 2011; Melbourne, Australia.
14. Bettinger JA, Scheifele DW, Halperin SA, et al. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine [published online ahead of print April 12, 2013]. doi: 10.1016/j.vaccine.2013.03.063.
15. Department of Health. Immunisation Against Infectious Diseases: The Green Book. Available at: https://www.gov.uk/government/organisations/public-health- england/series/immunisation-against-infectious-disease-thegreen- book. Accessed July 15, 2013.
16. Kitchin N, Southern J, Morris R, et al. Antibody persistence in UK preschool children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussiscontaining quadrivalent vaccine. Vaccine. 2009;27: 5096-5102.
17. Novartis Vaccines. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine. NCT01026974. 2012- [cited 2013 15 July]. Available from: http://clinicaltrials.gov/ct2/show/NCT0 1026974?term=V72P9E1&rank=1 NLM Identifier: NCT01026974.
18. Saroey P, Snape MD, John, TM, et al. Persistence of bactericidal antibodies following early infant immunisation with serogroup B meningococcal vaccines and immunogenicity of pre-school booster doses. Presented at: 30th Annual Meeting of the European Society for Paediatric Infectious Disease; Thessaloniki, Greece; May 8-12, 2012.
19. Novartis Vaccines. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine. 2009 - [cited 2013 15 July]. Available at: http://clinicaltrials.gov/ct2/show/NCT01027351?term=p6E1&rank= 2 NLM Identifier: NCT01027351.
20. Novartis Vaccines. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers. 2009 - [cited 2013 15 July]. Available at: http://clinicaltrials.gov/ ct2/show/NCT00847145?term=V72P13&rank=1 NLM Identifier: NCT00847145.